Summit Securities Group’s PAVmed PAVM Stock Holding History

Summit Securities Group’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-120	Closed	-$8K	–	725
2024 Q1	$8K	Buy	+120	New	+$9.07K	﹤0.01%	354

Other funds holding PAVM

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axiom Advisory San Diego, California $10.7B AUM 25.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

XML Financial Bethesda, Maryland $1.24B AUM 20.4% 1-Year Est. Return

Summit Securities Group's PAVM Position: Q2 2024 in Review

Summit Securities Group sold out of PAVmed (PAVM) in Q2 2024, closing a stake of 120 shares — an estimated $8K sold.

Summit Securities Group first reported a position in PAVM in Q1 2024 and held it in 1 quarter. The position peaked at $8K in Q1 2024. 22 funds tracked by Wall St. Rank hold PAVM as of Q2 2024.

Summit Securities Group reported no remaining PAVmed position as of Q2 2024 after selling out during the quarter.
Summit Securities Group sold 120 PAVmed shares in Q2 2024, an estimated $8K.
Summit Securities Group first reported a position in PAVmed in Q1 2024 and held it in 1 quarter.
Summit Securities Group's PAVmed position peaked at $8K in Q1 2024.
22 funds tracked by Wall St. Rank held PAVmed as of Q2 2024.

Based on Summit Securities Group's 13F filing for Q2 2024, filed 26 Jul 2024.